Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

6 Jul 2018

Abstract excerpt

Abstract Purpose: DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to DNA Repair Mechanisms
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29980530
DOI: 10.1158/1078-0432.ccr-18-1001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerPMID 29980530Read ↗

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataSemantic proximity Read ↗

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancerSemantic proximity Read ↗

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.Semantic proximity Read ↗

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Semantic proximity Read ↗

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder CancerSemantic proximity Read ↗

Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer.Semantic proximity Read ↗

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial CancerSemantic proximity Read ↗

Testing the metal of ERCC2 in predicting the response to platinum-based therapy.Semantic proximity Read ↗

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.Semantic proximity Read ↗

Low MSH2 protein levels identify muscle-invasive bladder cancer resistant to cisplatinSemantic proximity Read ↗

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.